Cargando…
Daratumumab therapy for post-HSCT immune-mediated cytopenia: experiences from two pediatric cases and review of literature
BACKGROUND: Immune-mediated cytopenias (AIC) are challenging complications following allogeneic hematopoietic stem cell transplantation (HSCT). While broad-acting immunosuppressive agents like corticosteroids are often standard of care, several novel therapies which target specific immunological pat...
Autores principales: | Driouk, Lina, Schmitt, Robert, Peters, Anke, Heine, Sabine, Girschick, Hermann Josef, Strahm, Brigitte, Niemeyer, Charlotte M., Speckmann, Carsten |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8085143/ https://www.ncbi.nlm.nih.gov/pubmed/33914175 http://dx.doi.org/10.1186/s40348-021-00114-y |
Ejemplares similares
-
Missing Cells: Pathophysiology, Diagnosis, and Management of (Pan)Cytopenia in Childhood
por: Erlacher, Miriam, et al.
Publicado: (2015) -
Daratumumab, an original approach for treating multi-refractory autoimmune cytopenia
por: Crickx, Etienne, et al.
Publicado: (2021) -
Immune-mediated cytopenias (IMCs) after HSCT for pediatric non-malignant disorders: epidemiology, risk factors, pathogenesis, and treatment
por: Spadea, Manuela, et al.
Publicado: (2023) -
Newly onset cytopenias not always indicate a relapsing AML after allogeneic HSCT, a case of non-destructive post transplant lymphoproliferative disorder
por: Yiğit Kaya, Süreyya, et al.
Publicado: (2023) -
Autoimmune Cytopenias in Pediatric Hematopoietic Cell Transplant Patients
por: Neely, Jessica A., et al.
Publicado: (2019)